DANCANN PHARMA A/S: Financial statements 2020
CVR: 39426005
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
DANCANN PHARMA A/S (CVR 39426005) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -4,829,650 and a net result of DKK -4,254,612 compared with DKK -1,239,612 the year before. Equity in the 2020 report amounted to DKK 44,325,536. The solvency ratio was 89.5%. The company had 4 employees in the financial year.
- Gross Profit
- DKK -4,829,650
- Profit/Loss
- DKK -4,254,612
- Equity
- DKK 44,325,536
- Total Assets
- DKK 49,548,660
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -4.8 mio. | -4.3 mio. | 44.3 mio. | 4 |
| 2019 | - | -422 t. | -1.2 mio. | -1.4 mio. | 4 |
Official annual report
How creditworthy is DANCANN PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of July 6, 2020, Jeppe Krog Rasmussen has joined the board of directors of DANCANN PHARMA A/S.
On July 6, 2020, the company changed its name from DANCANN PHARMA ApS to DANCANN PHARMA A/S.
On June 26, 2020, the company changed its name from DANCANN PHARMA IVS to DANCANN PHARMA ApS.
As of April 8, 2020, A/S PSE 17 NR. 1056 has been appointed auditor of DANCANN PHARMA A/S.
As of April 8, 2020, Carsten Trads has joined the board of directors of DANCANN PHARMA A/S.
As of April 8, 2020, Magnus Østergaard Dahlmann has joined the board of directors of DANCANN PHARMA A/S.
As of April 8, 2020, Per Wester has joined the board of directors of DANCANN PHARMA A/S.
DANCANN PHARMA A/S has published its annual report for 2019. Gross profit came to DKK -421,797, and the net result was DKK -1,239,612.
About DANCANN PHARMA A/S
DANCANN PHARMA A/S is a Danish company of the type Aktieselskab based in Ansager, founded in 2018. The company is under bankruptcy. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named DANCANN PHARMA ApS and DANCANN PHARMA IVS. The company is owned by JEQ Capital AB. The company has 1 employee (2026). In 2024, the company reported a gross profit of DKK -148,000 and a net result of DKK -8,346,000 compared with DKK -62,260,000 the year before. Equity in the 2024 report amounted to DKK 14,620,000.